Psychiatr. praxi. 2023;24(3):182-190 | DOI: 10.36290/psy.2023.034
Differences between brexpiprazole and aripiprazole in clinical practice. Case series
- 1 Psychiatrická a psychoterapeutická ordinace, Karlovy Vary
- 2 Národní ústav duševního zdraví, Klecany
- 3 Psychiatrická a psychologická klinika 3. LF UK, Praha
- 4 Psychiatrická klinika 1. LF UK a VFN, Praha
- 5 Oddělení psychiatrie FN a Katedra klinických neurověd LF Ostravská univerzita, Ostrava
- 6 Denní psychoterapeutické sanatorium „Ondřejov“, s. r. o., Praha
- 7 Psychiatrická ambulance Centrum Psychiatrie, Praha
- 8 Psychiatrická ambulance, EUC klinika, Plzeň
- 9 Clinline, s. r. o. – psychiatrická ambulance, Hořovice
- 10 Psychiatrická a psychoterapeutická ordinace, Karlovy Vary
Brexpiprazole is a new atypical antipsychotic acting as serotonin and dopamine modulator. Its mechanism of action is based on partial agonism on serotonin 5-HT1A receptors, antagonism at serotonin 5-HT2A receptors, partial agonism at dopamine D2 receptors and antagonism at two noradrenergic receptors, type α1B and type α2C. Due to its effect on dopamine D2 receptors brexpiprazole belongs to dopamine receptor partial agonists (DRPA). It has been introduced to clinical practice in treatment recently. Its profile is characterized by good antipsychotic efficacy and outstanding tolerability. Low incidence of side-effects is associated with treatment compliance, minimalization of relapse risk and a good functioning in life. This article presents a set of ten case reports from clinical practice, in which brexpiprazole in comparison with aripiprazole was linked to better treatment results. This presentation shows that antipsychotics from a DRPA group are not identical and brings the evidence that brexpiprazole is unique in some clinical situations.
Keywords: brexpiprazole, aripiprazole, schizophrenia, side effects.
Accepted: October 9, 2023; Published: October 16, 2023 Show citation
| ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- Kopeček M, Švancer P, Masopust J. Novinky v léčbě schizofrenie. Psychiatrie. 2022;26:87-93.
- Masopust J, Kopeček M, Protopopová D. Stabilizační a udržovací léčba schizofrenie. Doporučené postupy psychiatrické péče 2018 (aktualizovaná verze 2022). Available from: https://postupy‑pece.psychiatrie.cz/specialni‑psychiatrie/f2-schizofrenie/stabilizacni‑udrzovaci‑lecba‑schizofrenie.
- Kopeček M, Masopust J, Hubeňák J, et al. Brexpiprazol v klinické praxi aneb umění léčby směřující k funkční remisi schizofrenie. Čes a slov Psychiat 2021;117(6):283-289.
- Ustohal L. Srovnání nových antipsychotik (lurasidonu, kariprazinu a brexpiprazolu) z klinického úhlu pohledu. Psychiatr praxi. 2021;22(2):84-88.
- Citrome L. Aripiprazole, brexpiprazole, and cariprazine: not all the same. Current Psychiatry. 2018;17(4):24-34.
- Masopust J, Mohr P, Kopeček M. Parciální dopaminoví agonisté: stejní nebo odlišní? Psychiatrie. 2021;25:39-50.
- Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol. 2017;7(1):29-41.
Go to original source... 
Go to PubMed... - Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin‑dopamine activity modulator. J Pharmacol Exp Ther. 2014;350:589-604. Go to original source... Go to PubMed...
- Correll CU, He Y, Therrien F, et al. Effects of Brexpiprazole on Functioning in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long‑Term Studies. J Clin Psychiatry. 2022; 83(2):20m13793. Go to original source... Go to PubMed...